“Cutting the Support” to Improve Treatment Efficacy in Thyroid Cancer by Targeting Tumor Microenvironment
- 20 October 2021
- journal article
- editorial
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (4), E1758-E1759
- https://doi.org/10.1210/clinem/dgab685
Abstract
Tumor microenvironment (TME) is an essential component that provides optimal conditions for cancer cells to thrive, escape immune surveillance, invade, and metastasize. In addition to supporting cancer growth and progression, TME plays a critical role in cancer cell survival and therapeutic resistance. Thus, it is not surprising that the treatments that are effective in in vitro models lacking TME often fail to show efficacy in vivo. It is believed that oncogenic mutations and other pathogenic dysregulations cause cancer initiation. To survive in the new environment, the cancer cells recruit and transform noncancer TME cells by various cytokines, chemokines, and vesicles containing signaling proteins and alter the TME to...Keywords
This publication has 7 references indexed in Scilit:
- Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational InsightsJournal of Clinical Endocrinology & Metabolism, 2021
- The Emerging Roles of Pericytes in Modulating Tumor MicroenvironmentFrontiers in Cell and Developmental Biology, 2021
- The Fire within: Cell-Autonomous Mechanisms in Inflammation-Driven CancerCancer Cell, 2019
- Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 AxisClinical Cancer Research, 2018
- Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressureOncotarget, 2018
- Endothelial/Pericyte InteractionsCirculation Research, 2005
- Heterogeneous Distribution of Tumor Blood Supply Affects the Response to Chemotherapy in Patients with Head and Neck CancerMicrocirculation, 2000